Passage Total Revenue from 2010 to 2024

PASG Stock  USD 0.76  0.02  2.56%   
Passage Bio's Total Revenue is steady over the last several years with stable swings. Total Revenue is predicted to flatten to 0.00. Total Revenue is the total amount of income generated by the sale of goods or services related to Passage Bio's primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2019-03-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
1.2 M
 
Covid
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.52. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
  
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Currently Active Assets on Macroaxis

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.34)
Return On Equity
(0.64)
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.